Guides.
Plain-English, sourced explainers: what peptides actually are, technique guides for injections and reconstitution, how to read bloodwork, and the reference layers underneath every profile: mechanisms, regulatory status, common myths, and a full glossary. No dosing advice, ever.
What peptides actually are, how the evidence behind them works, the real difference between research-grade and pharmaceutical-grade, and why "natural" tells you nothing about safety. No hype, no dosing advice. Just sourced information.
How GLP-1 and dual-agonist medications work, what the large randomised trials actually show, the difference between the approved drugs and compounded versions, why weight comes back after stopping, and what the current evidence says about muscle loss. Not medical or dosing advice.
How testosterone injections work: esters and their pharmacokinetics, the evidence behind intramuscular vs subcutaneous routes, injection site anatomy, technique, and what gets monitored. This covers the science and technique; dosing and protocol decisions belong with your prescriber.
The labs people on TRT, GLP-1, or peptide protocols tend to track: what each marker actually measures, why it's followed, what timing does to the numbers, and how to read the difference between a reference range and what's optimal for you. This explains markers. It does not interpret your specific results. That's your clinician's job.
What reconstitution is, why peptides ship as white powder, what happens if you choose the wrong diluent, the step-by-step technique that protects peptide integrity, how degradation actually works (and what signs to look for), and how long a reconstituted vial is realistically useful. This covers technique and the concentration math; it does not recommend doses.
The most searched question in this field is some version of "how long until it works." The honest answer depends entirely on whether anyone has measured it. For the GLP-1 receptor agonists there are large randomised trials that map the whole curve week by week. For most research peptides there is nothing comparable, and the timelines circulating online are reconstructed from personal anecdote, which is the least reliable evidence there is. This guide explains what the trial data actually shows, why transformation content misleads, and how to tell a biomarker moving apart from an outcome changing.
Why does one compound get injected once a week while another is discussed in terms of multiple administrations per day? The answer is almost entirely pharmacokinetics: how fast the body clears the molecule, and what medicinal chemists did to slow that down. This guide covers what half-life means, why unmodified peptides survive only minutes in plasma, the specific engineering strategies that extend them, why pulsatile and sustained signalling are biologically different rather than merely convenient, and how route of administration changes everything. No doses or schedules appear here.
Two topics dominate GLP-1 discussion outside clinical settings: taking less than the labeled amount, usually called microdosing, and obtaining the drug from a compounding pharmacy rather than as the approved product. Both are widely discussed and poorly documented. This guide explains what people mean by microdosing, why the approved labels escalate the way they do, what compounding actually is under United States law, how the drug shortage list created the compounded GLP-1 market and what happened when it ended, and what the specific documented risks are. It contains no schedules, protocols, or amounts.
Four kinds of risk, what a Certificate of Analysis actually proves, and populations where risk changes.
The pathways peptides act through: GLP-1, GHRH, ghrelin, melanocortin, and more.
Which tracked peptides are FDA-approved, investigational, or research-use-only.
The recurring peptide myths, and what the evidence actually supports.
Every term this site uses, defined, from agonist to WADA.